Pharmacokinetic and Metabolic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine

Summary:  Purpose: To characterize the metabolic profile of topiramate (TPM) in humans and to assess the influence of enzyme induction by carbamazepine (CBZ) on the pharmacokinetics and metabolic profile of TPM.

[1]  E. Perucca,et al.  The effect of carbamazepine on the 2-hydroxylation of desipramine , 1995, Psychopharmacology.

[2]  T. Tomson,et al.  Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) , 2004, Epilepsy Research.

[3]  R. Nayak,et al.  Steady‐State Pharmacokinetics of Topiramate and Carbamazepine in Patients with Epilepsy During Monotherapy and Concomitant Therapy , 1996, Epilepsia.

[4]  G. Pledger,et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages , 1996, Neurology.

[5]  R. Anziano,et al.  The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. , 2000, British journal of clinical pharmacology.

[6]  R. Grimaldi,et al.  Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects , 2004, European Journal of Clinical Pharmacology.

[7]  G. Pledger,et al.  Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages , 1996, Neurology.

[8]  Wu Wn,et al.  Recent advances in biotransformation of CNS and cardiovascular agents. , 2000 .

[9]  E. Perucca,et al.  Influence of Dosage, Age, and Co-medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response , 2003, Therapeutic drug monitoring.

[10]  M. Bialer,et al.  Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic Patients , 2002, Epilepsia.

[11]  E. Perucca.  Clinical pharmacology and therapeutic use of the new antiepileptic drugs , 2001, Fundamental & clinical pharmacology.

[12]  W. Wu,et al.  Recent advances in biotransformation of CNS and cardiovascular agents. , 2000, Current drug metabolism.

[13]  E. Perucca,et al.  Topiramate Pharmacokinetics in Children and Adults with Epilepsy , 2005, Clinical pharmacokinetics.

[14]  W. Garnett.  Clinical Pharmacology of Topiramate: A Review , 2000, Epilepsia.

[15]  R. Nayak,et al.  Single‐Dose Pharmacokinetics and Effect of Food on the Bioavailability of Topiramate, A Novel Antiepileptic Drug , 1996, Journal of clinical pharmacology.

[16]  R. Shank,et al.  Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. , 1987, Journal of medicinal chemistry.

[17]  R. Twyman,et al.  Pharmacokinetic Interactions of Topiramate , 2004, Clinical pharmacokinetics.

[18]  M. Contin,et al.  Topiramate Therapeutic Monitoring in Patients With Epilepsy: Effect of Concomitant Antiepileptic Drugs , 2002, Therapeutic drug monitoring.

[19]  S. Nortey,et al.  Synthesis of hydroxylated derivatives of topiramate, a novel antiepileptic drug based on D-fructose: investigation of oxidative metabolites. , 1997, Carbohydrate research.

[20]  S. Johannessen.  Seventh Eilat Conference on New Antiepileptic Drugs (Eilat VII) , 2002, Seizure.

[21]  E. Perucca,et al.  The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. , 1993, British journal of clinical pharmacology.

[22]  E. Perucca,et al.  Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. , 2003, British journal of clinical pharmacology.

[23]  Kiyoshi Yamaoka,et al.  Statistical moments in pharmacokinetics , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  E. Perucca,et al.  Analysis of Topiramate and Its Metabolites in Plasma and Urine of Healthy Subjects and Patients With Epilepsy by Use of a Novel Liquid Chromatography–Mass Spectrometry Assay , 2003, Therapeutic drug monitoring.

[25]  Y. Blanco,et al.  Topiramate Serum Concentration-to-Dose Ratio: Influence of Age and Concomitant Antiepileptic Drugs and Monitoring Implications , 2004, Therapeutic drug monitoring.